RG-7420 |
GDC-0973 |
COTELLIC |
COBIMETINIB |
XL-518 |
RG-7421 |
XL 518 |
GDC0973 |
XL518 |
RG7420 |
GDC 0973 |
RG 7420 |
pubchem.compound:16222096 |
chemidplus:934660-93-2 |
rxcui:1722365 |
chembl:CHEMBL2146883 |
drugbank:05239 |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Melanoma (with BRAF V600E or V600K mutation) |
Drug Class | Kinase Inhibitor |
Pharmaceutical Developer | Exelixis |
Source Reported Drug Name(s) | GDC-0973/XL518 |
Drug Class | MEK Inhibitor |
Notes | allosteric inhibitor |
Drug Class | Kinase Inhibitors |
allosteric modulator |
inhibitor (inhibitory) |
n/a |
allosteric modulator |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
allosteric modulator |
inhibitor (inhibitory) |
Mechanism of Interaction | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor |
Direct Interaction | yes |
n/a |
Approval Status | FDA approved |
Approval Status | Phase Ib/II |
combination therapy | Atezolizumab + Vemurafenib + Cobimetinib |
n/a |
combination therapy | Atezolizumab + Cobimetinib |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted – sensitive |
COTELLIC | Trade Name |
Drug Class | Kinase Inhibitor |
FDA Approval | Melanoma (with BRAF V600E or V600K mutation) |
GDC-0973 | PubChem Drug Name |
16222096 | PubChem Drug ID |
XL518 | Drug Trade Name |
Drug Class | MEK Inhibitor |
Source Reported Drug Name(s) | GDC-0973/XL518 |
Pharmaceutical Developer | Exelixis |
GDC-0973 | Development Name |
Drug Class | Kinase Inhibitors |
Notes | allosteric inhibitor |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
D0O2FN | TTD Drug ID |
GDC-0973 | Primary Drug Name |
GDC-0973 | Drug Synonym |
XL518 | Drug Synonym |